However, repeated high-dose dronabinol appeared to result in selective tolerance to these effects.

HIV-negative marijuana smokers require higher than recommended dronabinol doses to experience expected effects.

Conclusions: In HIV-positive marijuana smokers, high dronabinol doses safely and effectively increased caloric intake.

During active dronabinol dosing, significant dose-dependent increases in THC and 11-OH-THC concentrations support withdrawal symptom suppression.

Results: Despite sustained increases in self-reported food cravings, dronabinol only increased caloric intake in the initial 8 days of dosing.

Conclusions: The significant withdrawal effects noted during placebo dronabinol administration were supported by significant plasma THC and 11-OH-THC concentration decreases.

These findings indicate that HIV-positive individuals who smoke marijuana may require higher dronabinol doses than are recommended by the FDA.

Generic dronabinol costs about $4 for each low-dose pill, or up to $15 per high-dose pill.

Its antiemetic properties have been exploited since the 1980s in a number of common medicines, including dronabinol and nabilone, to treat nausea induced by chemotherapy.

Dronabinol was well tolerated, causing few negative subjective or cognitive effects.

Dronabinol's mood-enhancing effects were sustained across the 16-day inpatient stay.